UK Location Enhances Employee and Customer Engagement
Alderley Edge, U.K., 29 May 2023 – Catalyst Clinical Research, a market leader in clinical research services, is pleased to announce the opening of its new office in the Alderley Park life science and innovation complex. The space was strategically designed to best serve the interests of employees and customers alike in this post-pandemic environment.
The choice to open the new office comes as Catalyst addresses the work environment influenced by the COVID-19 pandemic. Since 2018, Catalyst has occupied an office suite within Alderley Park more conducive to pre-pandemic work. Collaborations between the company’s hybrid teams and those of its customers and partners can be better accommodated at #11. As a culture-first organization, supporting the needs of nearby employees, both in and out of the office, was Catalyst’s top priority.
“The new office reflects our commitment to our European operations and our dedication to providing team members in the region with a workplace option where they can be productive and comfortable,” said Nick Dyer, CEO of Catalyst Clinical Research. “We wanted a space for in-person collaboration, when necessary, one that offers guests and employees a better experience overall.”
Catalyst strengthened its European commitment earlier this year by hiring two Europe-based executives in Data Sciences and Project Management—both firsts for the U.S.-headquartered company. They join a group of Europe-based Catalyst leaders managing key areas, including Quality, Privacy, Finance, Consulting Solutions, and more. The roles help serve the company’s growing number of employees in the region, many of whom joined following Catalyst’s acquisition of Aptus Clinical in 2022. Additionally, Catalyst’s expanding portfolio of European customers reflects the impact of the company’s strategic expansion efforts in Europe.
“Our new space is a realization of listening to our employees, understanding their needs, and delivering on promises outlined last year to reaffirm the company’s commitment to the region,” Dyer continued. “It’s an exciting time to be Catalyst in Europe.”
Catalyst Clinical Research is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm. For more information, visit CatalystCR.com.
About Catalyst Clinical Research
Catalyst is a clinical research organization (CRO) that provides highly customizable solutions to the global biopharmaceutical industry through two established, branded solutions: Catalyst Oncology and Catalyst FLEX. The company provides full-service oncology CRO offerings through Catalyst Oncology and multi-therapeutic resourcing and functional services through Catalyst FLEX. With over 800 staff and offices in the United States and Europe, Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies. Visit Catalyst online at CatalystCR.com. Follow us on Facebook, Twitter, and LinkedIn: @CatalystCR.
Catalyst is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm.
